+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID06932003

Exploring Safety, Tolerability, and Effectiveness of Oral LT-002-158 Tablets in Chinese Adults With Moderate-to-Severe Hidradenitis Suppurativa

Led by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Updated on 2026-08-27

12

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase IcII clinical trial to study the safety, tolerability, and effectiveness of LT-002-158 tablets in Chinese adults with moderate-to-severe hidradenitis suppurativa HS, a chronic skin condition. The Phase Ic portion is an open-label, single-arm study focused on safety and tolerability, while the Phase II portion is a randomized, double-blind, placebo-controlled trial followed by an open-label extension to assess therapeutic effects. Participants will receive LT-002-158 tablets orally once daily. The study includes two parts the initial Phase Ic safety evaluation and the Phase II randomized comparison with placebo, followed by an extension where all participants may receive the study drug. Treatments are given over a period of up to 42 days, with close monitoring of drug levels in the blood. Throughout the study, participants will undergo assessments including monitoring for adverse events, blood tests to measure drug concentration, and clinical evaluations of their skin condition. They will complete diaries and follow protocol requirements under investigator supervision. Safety and efficacy data will be collected up to 42 days, with the entire study lasting until the end of 2028.

CONDITIONS

Brief Title

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa

Research Team

J

Juan Xu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here